Compare Crispr Therapeutics AG (CRSP) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Genuine Parts Company — how do they compare? Crispr Therapeutics AG trades at $50.94 (market cap $4.88B), while Genuine Parts Company trades at $127.17 (market cap $17.67B). The key difference: Genuine Parts Company is far larger — about 3.6× Crispr Therapeutics AG's market cap, and Genuine Parts Company pays a 3.32% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Genuine Parts Company for 75 Days on average.
| CRSP | GPC | |
|---|---|---|
Market Cap | $4.88B | $17.67B |
Volume | 2,861,747 | 1,079,458 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $149.26 |
52-Week Low | $44.34 | $92.47 |
Typical Hold Time | 77 Days | 75 Days |
Enterprise Value | $3.30B | $23.76B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.
The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
